In a parallel‐design RCT, 72‐hour infusion of GLP‐1 did not reduce intravenous insulin requirement nor the rate of hypoglycaemia compared with saline control, although there was less plasma glucose variability with GLP‐1. This evidence concerns the gene GCG and Hypoglycemia.